Budget 2024: Govt Plans to fully Exempt 3 cancer drugs from customs duty

The government suggested completely waiving custom duties for three cancer drugs. Finance Minister Nirmala Sitharaman suggested exempting three additional medicines from customs duties in order to help cancer patients, during the...

ViroCell Biologics Inks Pact with NCI Designated Cancer Center

ViroCell Biologics, a company focused on cell and gene therapy contract development and manufacturing, has signed a five-year agreement with a leading U.S. cancer center for GMP viral vector manufacturing for clinical trials. The cancer center...

Grunenthal Acquires Valinor Pharma For USD 250 Million

The acquisition of Valinor Pharma, LLC (Valinor) and its product Movantik (naloxegol) was announced by Grünenthal, a top company in pain management and related illnesses, with a total cost of around $250 million including royalty obligations...

Rusan Pharma's API Plant in Ankleshwar Bags USFDA GMP Approval

RUSAN PHARMA PRIVATE LIMITED, a pharmaceutical company headquartered in India that focuses on addiction treatment and pain management, has just confirmed that its Active Pharmaceutical Ingredient (API) facility in Ankleshwar (Gujarat, India) has...

Budget 2024: What Pharma Industry Expects

While India anticipates the Union Budget 2024, the pharmaceutical industry in India is looking forward to initiatives that will improve their expansion and reinforce India's standing as a global leader. At present, the pharmaceutical industry is...

MHRA Approves First Generic Raltegravir Medicines For HIV Treatment

The first generic raltegravir medications for treating adult and pediatric HIV patients weighing at least 40kg have been authorized by the UK Medicines and Healthcare products Regulatory Agency (MHRA). HIV is responsible for AIDS, which...

© 2024 India Pharma Outlook. All Rights Reserved.